Novartis said Thursday it will spend $23 billion over the next five years to expand in the U.S. The drugmaker expects this will create about 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis. The company will be able to make domestically all of its medicines for the U.S., it added.

Swiss drugmaker Novartis (NOVN.S) said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration. Novartis said it plans to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well as a new research and development site in San Diego, California. Novartis' drugs, including heart failure medicine Entresto and breast cancer therapy Kisqali, are manufactured across 33 sites globally. The new sites and extensions will be built over the next five years and are expected to create more than 1,000 jobs for skilled workers like engineers and scientists as well as another 3,000 support staff and construction jobs, Novartis said.

The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis, the company said. It will enable Novartis to make domestically all of its medicines for the U.S., it added. The announcement comes as the pharmaceutical industry braces for potential tariffs on drugs imported into the U.S. Medicines were exempted from last week’s executive order, but industry officials and lobbyists are still preparing for them at some point. President Trump said this week the pharmaceutical tariffs would be coming “very shortly.” Trump on Wednesday spoke on the phone with Swiss President Karin Keller-Sutter, she said on X.

By Patrick Wingrove (Reuters) -Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration. The drugmake...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites. Between November 2024 and March 2025, Novartis laid off around 4,000 jobs in the country.